SAN

77.23

+0.93%↑

ARGX

698.2

+0.11%↑

SHL.DE

34.84

+0.11%↑

FRE

38.2

-0.24%↓

PHIA

23.59

+0.47%↑

SAN

77.23

+0.93%↑

ARGX

698.2

+0.11%↑

SHL.DE

34.84

+0.11%↑

FRE

38.2

-0.24%↓

PHIA

23.59

+0.47%↑

SAN

77.23

+0.93%↑

ARGX

698.2

+0.11%↑

SHL.DE

34.84

+0.11%↑

FRE

38.2

-0.24%↓

PHIA

23.59

+0.47%↑

SAN

77.23

+0.93%↑

ARGX

698.2

+0.11%↑

SHL.DE

34.84

+0.11%↑

FRE

38.2

-0.24%↓

PHIA

23.59

+0.47%↑

SAN

77.23

+0.93%↑

ARGX

698.2

+0.11%↑

SHL.DE

34.84

+0.11%↑

FRE

38.2

-0.24%↓

PHIA

23.59

+0.47%↑

Home・Akciju saraksts・Fagron

Fagron

Atvērts

SektorsVeselības aprūpe

25.1 0.2

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

25.2

Galvenie mērījumi
By Trading Economics
Ienākumi	-99K 45M
Pārdošana	-98K 476M
P/E Sektora vidējais	19.597 49.701
Dividenžu ienesīgums	1.66
Peļņas marža	9.55
Darbinieki	4,193
EBITDA	11M 98M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+20.59% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	1.66% 2.39%
Nākamie ieņēmumi	2026. g. 30. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	153M 1.8B
Iepriekšējā atvēršanas cena	24.9
Iepriekšējā slēgšanas cena	25.1

Ziņu noskaņojums

By Acuity

50%

159 / 345 Rangs Healthcare

Fagron Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 25. maijs 08:24 UTC

Galvenie tirgus virzītāji

Iegādes, apvienošanās, pārņemšana

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

2026. g. 25. maijs 21:22 UTC

Peļņas

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

2026. g. 25. maijs 20:50 UTC

Tirgus saruna

Peļņas

Basic Materials Roundup: Market Talk

2026. g. 25. maijs 16:20 UTC

Tirgus saruna

Peļņas

Basic Materials Roundup: Market Talk

2026. g. 25. maijs 16:01 UTC

Tirgus saruna

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

2026. g. 25. maijs 14:43 UTC

Tirgus saruna

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

2026. g. 25. maijs 14:15 UTC

Tirgus saruna

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

2026. g. 25. maijs 13:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 25. maijs 12:58 UTC

Tirgus saruna

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

2026. g. 25. maijs 12:56 UTC

Tirgus saruna

Peļņas

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

2026. g. 25. maijs 12:48 UTC

Tirgus saruna

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

2026. g. 25. maijs 12:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 25. maijs 12:34 UTC

Tirgus saruna

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

2026. g. 25. maijs 12:10 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Delivery Hero's Assets Look Strategic -- Market Talk

2026. g. 25. maijs 11:00 UTC

Tirgus saruna

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

2026. g. 25. maijs 10:19 UTC

Tirgus saruna

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

2026. g. 25. maijs 10:05 UTC

Peļņas

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

2026. g. 25. maijs 10:04 UTC

Peļņas

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

2026. g. 25. maijs 10:03 UTC

Peļņas

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

2026. g. 25. maijs 10:02 UTC

Peļņas

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

2026. g. 25. maijs 10:01 UTC

Peļņas

Tenaga Nasional 1Q Net Up 3.7% on Year

2026. g. 25. maijs 10:00 UTC

Peļņas

Tenaga Nasional 1Q Rev Up 6.6% on Year

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional 1Q EPS MYR0.1883

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional 1Q Rev MYR17.1B

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional 1Q Net MYR1.1B

2026. g. 25. maijs 09:38 UTC

Tirgus saruna

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

2026. g. 25. maijs 09:33 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 25. maijs 09:33 UTC

Tirgus saruna

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

2026. g. 25. maijs 08:55 UTC

Tirgus saruna

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Salīdzinājums

Cenas izmaiņa

Fagron Prognoze

Cenas mērķis

By TipRanks

20.59% augšup

Prognoze 12 mēnešiem

Vidējais 19.5 EUR 20.59%

Augstākais 19.5 EUR

Zemākais 19.5 EUR

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Fagron — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Fagron — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

159 / 345 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.